Mark For: ELAREF® trademark registration is intended to cover the category of
Research | OneLook Acronym Finder |
Serial Number | 76204386 |
Registration Number | 2751762 |
Mark Literal Elements | ELAREF |
Mark Drawing Type | 1 - TYPESET WORD(S) /LETTER(S) /NUMBER(S) |
Mark Type | TRADEMARK |
Standard Character Claim | No |
Register | PRINCIPAL |
Current Location | SCANNING ON DEMAND 2008-03-10 |
Basis | 44(e) |
Class Status | SECTION 8 - CANCEL |
Primary US Classes |
|
Primary International Class |
|
Filed Use | No |
Current Use | No |
Intent To Use | No |
Filed ITU | Yes |
44D Filed | No |
44E Current | Yes |
66A Current | No |
Current Basis | No |
No Basis | No |
Cancellation Code | 2 |
Domestic Representative | Wm. Charles Saunders |
Attorney Name | Wm. Charles Saunders |
Law Office Assigned | M60 |
Employee Name | KIM, YONG OH |
2001-02-02 | Application Filed |
2003-05-27 | Published |
2003-05-27 | Published for Opposition |
2003-08-19 | Trademark Registered |
2008-03-10 | Location: SCANNING ON DEMAND |
2010-03-27 | Cancelled |
2010-03-27 | Status: Dead/Cancelled |
2010-03-27 | Status: Registration cancelled because registrant did not file an acceptable declaration under Section 8. To view all documents in this |
2018-07-08 | Transaction Date |
Party: | AstraZeneca UK Limited |
Address | 15 Stanhope Gate London, W1Y 6LN ENGLAND |
Legal Entity Type | Limited Liability Company |
Legal Entity State | UNITED KINGDOM |
Application | IMAGE/TIFF | 2001-02-02 |
Drawing | IMAGE/TIFF | 2001-02-02 |
Offc Action Outgoing | 2003-01-28 | |
XSearch Search Summary | 2003-01-28 | |
Fax Incoming | 2003-02-04 | |
Paper Correspondence Incoming | 2003-02-04 | |
Notice of Publication | 2003-05-07 | |
Registration Certificate | 2003-08-19 | |
Registration Certificate | 2003-08-19 | |
TEAS Rev, App and/or COA of Atty/Dom.Rep | 2007-07-31 | |
File Jacket | 2008-03-04 | |
Unclassified | 2008-03-04 |
(CANCELLED)
IC 005. US 006 018 044 046 051 052. G & S: Pharmaceutical preparations and substances for the prevention and/or treatment of cancer
International Codes: | 5 |
U.S. Codes: | 006,018,044,046,051,052 |
Type Code | Type |
---|---|
GS0051 | Pharmaceutical preparations and substances for the prevention and/or treatment of cancer |
Description | Date | Proceeding Number |
---|---|---|
CANCELLED SEC. 8 (6-YR) | 2010-03-27 | |
CASE FILE IN TICRS | 2008-03-10 | |
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2007-07-31 | |
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2007-07-31 | |
REGISTERED-PRINCIPAL REGISTER | 2003-08-19 | |
PUBLISHED FOR OPPOSITION | 2003-05-27 | |
NOTICE OF PUBLICATION | 2003-05-07 | |
APPROVED FOR PUB - PRINCIPAL REGISTER | 2003-03-14 | |
CORRESPONDENCE RECEIVED IN LAW OFFICE | 2003-02-04 | |
NON-FINAL ACTION MAILED | 2003-01-30 | |
ASSIGNED TO EXAMINER | 2002-09-09 | 75594 |
PETITION TO REVIVE-GRANTED | 2002-09-05 | |
ASSIGNED TO EXAMINER | 2002-04-08 | 75594 |
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | 2002-04-08 | |
PETITION TO REVIVE-RECEIVED | 2002-02-07 | |
NON-FINAL ACTION MAILED | 2001-06-04 | |
ASSIGNED TO EXAMINER | 2001-05-18 | 76582 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.